SIGA Technologies

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
SIGA Technologies, Inc.
Public
Traded asSIGA on Nasdaq
IndustryHealthcare – Biotechnology/Health Security
Founded1995
Headquarters
New York City
,
United States
Key people
Eric A. Rose M.D. (Chairman);

Phillip L. Gomez (CEO) Daniel J. Luckshire (Chief Financial Officer); Robin E. Abrams (General Counsel and Chief Administrative Officer)

Dennis E. Hruby Ph.D. (Chief Scientific Officer)
Productspharmaceutical agents
Number of employees
43 (November, 2018)
Websitewww.siga.com

SIGA Technologies, Inc. (NASDAQSIGA) is a public USA-based commercial stage pharmaceutical company engaged in health security development and the commercialization of solutions for biothreats and other unmet medical needs. [1][2][3][4][5]

SIGA’s lead product is TPOXX® (USAN tecovirimat, ST-246®), an orally administered antiviral approved in July 2018 by the U.S. Food and Drug Administration for the treatment of smallpox disease. TPOXX® has been delivered to the U.S. Strategic National Stockpile (“SNS”) under the Project BioShield Act of 2004.[6][7][8] [9]

About Health Security[edit]

Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks through the use of vaccines and therapies for emerging infectious diseases and health preparedness. Biodefense is a $9.5B annual global market.[10][11]Between 2001 and 2014, the U.S. government spent nearly $79B on civil biodefense funding

Government Relations[edit]

SIGA works with various U.S. Government agencies, including the Biodefense Advanced Research Development Authority (BARDA), which is responsible for late-stage clinical development and procurement of pharmaceutical countermeasures for the U.S. government.[12][13] SIGA has delivered 2 million courses of TPOXX® to the Strategic National Stockpile (SNS). Development of TPOXX was supported by the NIH, CDC and Department of Defense (DoD) to combat Category A pathogens using BSL-3 or -4 work, as well as BARDA.[14][15][16]

TPOXX[edit]

In July 2018, TPOXX® (USAN tecovirimat, ST-246®), an orally-administered anti-viral oral capsule was approved by the FDA for the treatment of human smallpox disease.[17] [18] TPOXX® is among the first new small-molecule drugs delivered to the Strategic National Stockpile (SNS) under the Project BioShield Act with BARDA. In Q3 2017, SIGA completed delivery of 2 million courses of TPOXX to the SNS under a 2013 $472 million contract. In September 2018, SIGA was awarded another BARDA contract valued at up to $629 million, if all options are exercised by BARDA. [19][20]

History[edit]

SIGA’s antiviral programs produce products to counteract pathogens and biodefense threats. The company’s bioinformatics infrastructure provides biological and chemical data for researchers to manage and study (such as data mining). The current discovery targets are influenza virus (H5N1, H2N1), Bunyavirus (Rift Valley Fever virus, La Crosse virus), filovirus (Marburg virus, Ebola virus), flavivirus (West Nile virus).[21]

In September 2009, SIGA Technologies received a $1.6 million research grant from the National Institutes of Health ("NIH") for its broad-spectrum antiviral candidates.[22]

In August 2011, SIGA Technologies was awarded a $7.7 million grant from the National Institutes of Health (NIH) to develop an antiviral drug for treating and preventing Lassa fever and others of Arenavirus origin.[23]

In 2011, SIGA was ordered to pay $232 million in damages in a legal dispute with PharmAthene over rights to the smallpox drug tecovirimat.[24]

In July 2013, SIGA Technologies delivered about 590,000 courses of its smallpox antiviral drug tecovirimat (Arestvy) to the United States Government's Strategic National Stockpile (SNS), meeting the requirement of Government's Biomedical Advanced Research and Development Authority (BARDA).[25]

In November 2013, SIGA laid off its entire research & development division located in Corvallis, Oregon. The company liquidated all laboratory equipment at auction from that site.

SIGA is a member of the Alliance for Biosecurity.[26] The alliance is a public-private partnership and coalition of biopharmaceutical companies and academic organizations that promotes that works to ensure medical countermeasures are available to protect public health and improve national health security.[27]

In 2014, SIGA filed for bankruptcy protection.[28]

In 2016, SIGA emerged from Chapter 11 bankruptcy protection after its amended reorganization plan was approved by the U.S. Bankruptcy Court for the Southern District of New York.[29]

Awards[edit]

In 2008, the company was selected as a winner of the Deloitte New York, New Jersey, Connecticut Technology Fast 50 Program for 2008. [30]

References[edit]

  1. ^ Editorial, Reuters. "${Instrument_CompanyName} ${Instrument_Ric} Company Profile | Reuters.com". U.S. Retrieved 2018-11-22.
  2. ^ Grosenbach, Douglas W.; Honeychurch, Kady; Rose, Eric A.; Chinsangaram, Jarasvech; Frimm, Annie; Maiti, Biswajit; Lovejoy, Candace; Meara, Ingrid; Long, Paul (2018-07-05). "Oral Tecovirimat for the Treatment of Smallpox". New England Journal of Medicine. 379 (1): 44–53. doi:10.1056/nejmoa1705688. ISSN 0028-4793. PMC 6086581. PMID 29972742.
  3. ^ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 2018-11-22.
  4. ^ Abott, C.C. "SIGA Technologies: A Buy For The Smallpox Treatment".
  5. ^ "SIGA Stock Price & News - SIGA Technologies Inc. - Wall Street Journal". quotes.wsj.com. Retrieved 2018-11-22.
  6. ^ Grosenbach, Douglas W.; Honeychurch, Kady; Rose, Eric A.; Chinsangaram, Jarasvech; Frimm, Annie; Maiti, Biswajit; Lovejoy, Candace; Meara, Ingrid; Long, Paul (2018-07-05). "Oral Tecovirimat for the Treatment of Smallpox". New England Journal of Medicine. 379 (1): 44–53. doi:10.1056/nejmoa1705688. ISSN 0028-4793. PMC 6086581. PMID 29972742.
  7. ^ "Siga Technologies touts pivotal data for oral smallpox therapy | Drug Delivery Business". Drug Delivery Business. 2018-07-05. Retrieved 2018-11-22.
  8. ^ "With Looming Bioterrorism Threats, FDA Approves First Smallpox Therapeutic | BioSpace". BioSpace. Retrieved 2018-11-22.
  9. ^ Lee, Bruce Y. "FDA Approves TPOXX To Be The First Drug For Smallpox". Forbes. Retrieved 2018-11-22.
  10. ^ "Antibiotics Market Size, Trends & Share | Industry Analysis Report, 2024". www.grandviewresearch.com. Retrieved 2018-11-22.
  11. ^ Sell, Tara Kirk; Watson, Matthew (September 2013). "Federal Agency Biodefense Funding, FY2013-FY2014". Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science. 11 (3): 196–216. doi:10.1089/bsp.2013.0047. ISSN 1538-7135. PMC 3778993. PMID 23906009.
  12. ^ Editorial, Reuters. "${Instrument_CompanyName} ${Instrument_Ric} Company Profile | Reuters.com". U.S. Retrieved 2018-11-22.
  13. ^ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 2018-11-22.
  14. ^ "Government Relations". www.siga.com. Retrieved 2018-11-22.
  15. ^ Editorial, Reuters. "${Instrument_CompanyName} ${Instrument_Ric} Company Profile | Reuters.com". U.S. Retrieved 2018-11-22.
  16. ^ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 2018-11-22.
  17. ^ Grosenbach, Douglas W.; Honeychurch, Kady; Rose, Eric A.; Chinsangaram, Jarasvech; Frimm, Annie; Maiti, Biswajit; Lovejoy, Candace; Meara, Ingrid; Long, Paul (2018-07-05). "Oral Tecovirimat for the Treatment of Smallpox". New England Journal of Medicine. 379 (1): 44–53. doi:10.1056/nejmoa1705688. ISSN 0028-4793. PMC 6086581. PMID 29972742.
  18. ^ Editorial, Reuters. "${Instrument_CompanyName} ${Instrument_Ric} Company Profile | Reuters.com". U.S. Retrieved 2018-11-22.
  19. ^ Grosenbach, Douglas W.; Honeychurch, Kady; Rose, Eric A.; Chinsangaram, Jarasvech; Frimm, Annie; Maiti, Biswajit; Lovejoy, Candace; Meara, Ingrid; Long, Paul (2018-07-05). "Oral Tecovirimat for the Treatment of Smallpox". New England Journal of Medicine. 379 (1): 44–53. doi:10.1056/nejmoa1705688. ISSN 0028-4793. PMC 6086581. PMID 29972742.
  20. ^ Editorial, Reuters. "${Instrument_CompanyName} ${Instrument_Ric} Company Profile | Reuters.com". U.S. Retrieved 2018-11-22.
  21. ^ "Company Research & Discovery".
  22. ^ "$1.6 Million NIH Cooperative Agreement Supports SIGA Broad Spectrum Antiviral Research".
  23. ^ "SIGA Awarded a $7.7 Million Grant for the Development of Antiviral Drugs for Arenaviruses".
  24. ^ "Smallpox Drug Maker Siga to Mediate PharmAthene Dispute". Bloomberg News. Oct 31, 2014.
  25. ^ "SIGA Meets Drug Delivery Condition Under BARDA Contract and Qualifies for First Payment for Delivering Arestvyr(TM)".
  26. ^ "Our Members". Alliance for Biosecurity. Retrieved 2017-03-07.[dead link]
  27. ^ "Our Mission". Alliance for Biosecurity. Retrieved 2017-03-07.[dead link]
  28. ^ "Siga Technologies Files for Bankruptcy Protection". The Wall Street Journal. Sep 16, 2014.
  29. ^ Gazette-Times, BENNETT HALL Corvallis. "Siga comes out of bankruptcy". Corvallis Gazette Times. Retrieved 2018-11-22.
  30. ^ "SIGATechnologies Named to Deloitte Tri-State Area Technology Fast 50".

External links[edit]